Compare · GNPX vs SLDB
GNPX vs SLDB
Side-by-side comparison of Genprex Inc. (GNPX) and Solid Biosciences Inc. (SLDB): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. GNPX focuses on Biotechnology: Pharmaceutical Preparations, while SLDB focuses on Biotechnology: Biological Products (No Diagnostic Substances).
- SLDB is the larger of the two at $718.8M, about 322.5x GNPX ($2.2M).
- Both names hit the wire about 9 times in the past 4 weeks.
- SLDB has more recent analyst coverage (19 ratings vs 0 for GNPX).
- Company
- Genprex Inc.
- Solid Biosciences Inc.
- Price
- -
- -
- Market cap
- $2.2M
- $718.8M
- 1M return
- -
- -
- 1Y return
- -
- -
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Biological Products (No Diagnostic Substances)
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2018
- 2018
- News (4w)
- 9
- 9
- Recent ratings
- 0
- 19
Genprex Inc.
Genprex, Inc., a clinical-stage gene therapy company, focuses on developing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for patient populations with cancer and diabetes who currently have limited treatment options. The company works with institutions and collaborators to develop drug candidates to further its pipeline of gene therapies in order to provide novel treatment approaches. Its lead product candidate is REQORSA (GPX-001), which is in preclinical stage for the treatment of non-small cell lung cancer (NSCLC). It is also developing GPX-002, a preclinical stage gene therapy for diabetes. The company also offers ONCOPREX, a nanoparticle delivery system. Genprex, Inc. was incorporated in 2009 and is headquartered in Austin, Texas.
Solid Biosciences Inc.
Solid Biosciences Inc., a life science company, engages in developing therapies for duchenne muscular dystrophy (DMD) in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles. Its portfolio also comprises Anti-LTBP4, a complementary disease modifying program that identifies and develops a monoclonal antibody intended to reduce fibrosis and inflammation by targeting and stabilizing the LTBP4 protein. In addition, the company engages in developing biomarkers and sensors; and Solid Suit program that includes the development of wearable assistive devices that focus on providing functional and therapeutic benefits. Solid Biosciences Inc. has strategic collaboration with Ultragenyx to develop and commercialize new gene therapies for Duchenne Muscular Dystrophy. Solid Biosciences Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
Latest GNPX
- Genprex Presents Preclinical Data Identifying TROP2 as a Potential Predictive Biomarker for Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 10-Q filed by Genprex Inc.
- Genprex to Highlight Dual Delivery Strategy for Diabetes Gene Therapy at Future of Cell and Gene Therapy Symposium
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Presents Data Showing Reqorsa® Gene Therapy Activates Cellular Repair and Maintenance Programs Linked to Aging Biology in Patients, Supporting TUSC2 as a Key Regulator of Resilience to Aging-Associated Stress
- Genprex Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits
- Genprex Announces New Research Identifying TROP2 as a Potential Predictive Biomarker to Reqorsa® Gene Therapy in Lung Cancer
- SEC Form 8-K filed by Genprex Inc.
- Genprex to Present TUSC2 Research from Sponsored Collaboration with Meharry Medical College at the Gerontological Society of America 2026 Annual Scientific Meeting
- SEC Form 8-K filed by Genprex Inc.
Latest SLDB
- SEC Form SCHEDULE 13G filed by Solid Biosciences Inc.
- Solid Biosciences to Participate in the 2026 Jefferies Global Healthcare Conference
- William Blair resumed coverage on Solid Biosciences
- Amendment: SEC Form SCHEDULE 13D/A filed by Solid Biosciences Inc.
- Solid Biosciences to Participate in the Guggenheim 3rd Annual Healthcare Innovation Conference
- Solid Biosciences Reports Third Quarter 2026 Financial Results and Provides Business Updates
- SEC Form 10-Q filed by Solid Biosciences Inc.
- SEC Form 4 filed by Solid Biosciences Inc.
- Solid Biosciences Announces European Commission Orphan Designation for SGT-212 and Continued Progress in the FALCON Trial in Friedreich’s Ataxia
- Chief Medical Officer Brooks Gabriel sold $24,582 worth of shares (4,374 units at $5.62) as part of a pre-agreed trading plan (SEC Form 4)